The objective of this registry is to gather clinical data on symptomatic patients with mitral valve disease, including patients with mitral regurgitation, mitral stenosis, and mixed mitral valve disease. Data collected from this registry are expected to improve our understanding of the impact of correcting symptomatic mitral valve disease on clinical outcomes in patients that could be candidates for Transcatheter Mitral Valve Replacement and may also inform future regulatory or reimbursement submission strategies for the Cephea Mitral Valve System.
Symptomatic mitral valve disease resulting in mitral regurgitation and/or severe mitral valve stenosis.
New York Heart Association (NYHA) Functional Class II, III, or ambulatory IV.
In the judgement of the Site Heart Team, transcatheter therapy is deemed to be more appropriate than conventional mitral valve surgery, TMVR is more likely to provide an optimal result than TEER, and the subject has been adequately treated per applicable standards, including for coronary artery disease, left ventricular dysfunction, and heart failure.
Age 18 years or older at time of consent.
Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function.
Subject is undergoing dialysis or experiencing chronic renal failure
Subject has chronic lung disease requiring continuous home oxygen therapy or chronic outpatient oral steroid use
Subjects with comorbidities that are likely to result in a life expectancy of less than 12 months.